924 material Form 8-K filings that 737 companies we cover made with the SEC in January 2026, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). All of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
On January 7, 2026, Arrowhead Pharmaceuticals agreed to sell $625 million of 0.00% convertible senior notes due 2032, upsized from $500 million, and 3,100,776 common shares at $64.50 per share. Underwriters exercised their over-allotment options in full on January 8, 2026. The filing says the offerings add shares and potential conversion shares, which could dilute existing shareholders, and that proceeds are for general corporate purposes and may partly prepay its Sixth Street credit facility.
Convertible notes: $625 million principal, 0.00% interest, maturing January 15, 2032; initial conversion price about $87.07 per share, a premium of about 35.0% to the $64.50 stock offering price.
Common stock: 3,100,776 shares at $64.50 each, plus a 456,116-share option exercised in full on January 8, 2026.
Expected net proceeds with options: about $681.3 million from the notes and $216.6 million from the stock; closings expected January 12, 2026 (notes) and January 9, 2026 (stock).
About $42.8 million of note proceeds will fund capped call transactions; the remainder is for general corporate purposes, and a portion may prepay Sixth Street Lending Partners loans.
Genelux Corporation agreed on January 8, 2026 to sell 6,666,667 new shares of common stock at $3.00 per share through an underwritten offering led by Lucid Capital Markets, expected to bring in about $20.0 million gross before underwriting discounts and expenses. The company says net proceeds will go to general corporate purposes, including research and development and clinical trial costs, and the new shares will dilute existing holders' ownership.
Offering of 6,666,667 shares at $3.00 per share, with gross proceeds of about $20.0 million before discounts and expenses
Underwriter has a 30-day option to buy up to 1,000,000 additional shares at the offering price
Closing is expected on or about January 9, 2026, subject to customary closing conditions
Proceeds are expected to fund general corporate purposes, including research and development and clinical trial expenses
Williams Companies completed a registered offering of $2.75 billion in senior unsecured notes on January 8, 2026, comprising $500 million of additional 5.650% notes due 2033, $1.25 billion of 5.150% notes due 2036 and $1 billion of 5.950% notes due 2056. The filing describes standard indenture terms, including covenants limiting liens and asset sales and optional redemption rights, and does not report any effect on the company's earnings or guidance.
Total offering of $2.75 billion across three tranches, completed January 8, 2026.
New 2033 Notes of $500 million are an add-on to $750 million of 5.650% notes issued March 2, 2023, and trade interchangeably with them.
Interest on the 2033 Notes is paid March 15 and September 15, beginning March 15, 2026; interest on the 2036 and 2056 Notes begins September 15, 2026.
Notes were issued under a Form S-3 registration statement and a prospectus supplement dated January 5, 2026.
Entergy Arkansas sold $500 million of 4.95% first mortgage bonds due 2036 and $500 million of 5.75% bonds due 2056, for $1 billion in total, with the sale closing on January 8, 2026. The bonds were issued under the company's effective automatic shelf registration statement. For shareholders, this is a routine debt financing and the filing does not state how the proceeds will be used.
Underwriting agreement dated January 5, 2026; sale of the bonds closed January 8, 2026
$500 million of 4.95% First Mortgage Bonds due January 15, 2036
$500 million of 5.75% First Mortgage Bonds due January 15, 2056
Terreno Realty Corporation's subsidiary entered a Fourth Amendment to its senior credit agreement on January 7, 2026, adding a $200.0 million term loan due January 15, 2031. Proceeds were used to reduce borrowings under the $600.0 million revolving credit facility and for general corporate purposes. The amendment also adds an accordion feature allowing the facility to grow by up to $1.0 billion, to a maximum of $2.0 billion, subject to lender approval.
New $200.0 million term loan matures January 15, 2031
Revolving credit facility of $600.0 million matures January 2029; two $100.0 million term loans mature in January 2027 and January 2028
Accordion feature allows aggregate facility size to rise to a maximum of $2.0 billion, subject to lender approval
Term loan interest margins range from 1.15% to 1.65% over SOFR, depending on leverage
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.